BioCryst Appoints Dr. Nancy Hutson as Chair of the Board
March 31, 2023 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors,...
BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success
March 29, 2023 16:01 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today acknowledged the many contributions of Robert A. Ingram, the company’s chairman...
CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada
March 08, 2023 15:00 ET
|
BioCryst Pharmaceuticals, Inc.
INTENDED FOR CANADIAN AUDIENCES ONLY RESEARCH TRIANGLE PARK, N.C., March 08, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2023 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., March 02, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors...
BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)
February 24, 2023 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
— Final safety and effectiveness analysis from APeX-S showed ORLADEYO 150 mg resulted in a median attack rate of 0.0 attacks per month in 20 of 24 months — RESEARCH TRIANGLE PARK, N.C., Feb. 24,...
BioCryst to Present at Upcoming Investor Conferences
February 22, 2023 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Cowen 43rd Annual Health Care...
BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
February 21, 2023 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
—ORLADEYO net revenue of $70.7 million for Q4 2022 and $251.6 million for FY 2022— —ORLADEYO net revenue in 2023 expected to be no less than $320 million— —ORLADEYO peak sales expected to be $1...
BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
February 07, 2023 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 07, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2022 financial results...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2023 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 06, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 03, 2023 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral,...